Like lecanemab before it, donanemab’s path to market has been slow and rocky. In the U.S., the antibody received Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback